TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

MOGRIFY

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

MOGRIFY

ST13

US500000079289697

Classe

1, 5, 9, 40, 42, 44

Pedido

79289697

Registro

6430514

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

32

Atualização mais recente

27/07/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 9, 40, 42, 44

Data de depósito

13/05/2020

Data de registro

27/07/2021

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

27/07/2021

Última transação

27/07/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

99

Localização do titular

GB

Examinador

MASON, JARED MICHAEL

Unidade examinadora

N10

Localização atual

PUBLICATION AND ISSUE SECTION

Titulares e representantes

Titulares

Mogrify Limited

Representantes

Rebecca Liebowitz Venable LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 9Classe 40Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

Reagents for research purposes; molecular biology research tools in the nature of biological, chemical and biochemical reagents for research use

Classe 5

Medical and veterinary preparations for therapeutic purposes, namely pharmaceutical and biopharmaceutical preparations for the treatment of ophthalmological conditions, hematologic diseases, immune response disorders, neurological disorders, respiratory diseases, metabolic diseases, genetic conditions, cancer, infectious diseases and cardiovascular diseases; pharmaceutical and biopharmaceutical preparations for cell therapy; pharmaceutical and biopharmaceutical preparations for modifying human or animal cells for medical or therapeutic purposes; biological, chemical and biochemical reagents for medical use

Classe 9

Downloadable bioinformatics software for genomic data analysis; downloadable computer software platforms for genomic data analysis in the fields of ophthalmology, haematology, immunology, neurology, respiratory diseases, metabolic conditions, genetic conditions, oncology, immuno-oncology, infectious diseases and cardiovascular diseases; scientific apparatus for measuring and analysing scientific study data in the nature of apparatus for recording, transmission or reproduction of data including video, audio, images and text; data analysis apparatus in the nature of data processing equipment and computers and downloadable operating computer software sold as a unit; downloadable scientific data analysis software

Classe 40

Treatment and processing of biological materials, namely cells, stem cells, induced pluripotent stem cells; custom manufacture of therapeutic drugs, namely custom manufacture of transcription factors, cells and cell therapies, gene therapies ; information, advisory and consultancy services in relation to all of the aforesaid services

Classe 42

Scientific and technological services, namely, research and design in the fields of ophthalmology, haematology, immunology, neurology, respiratory diseases, metabolic conditions, genetic conditions, oncology, immuno-oncology, infectious diseases and cardiovascular diseases; industrial research services in the field of cell therapies and gene therapies; medical and veterinary research services in the nature of the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in human and animal cell therapy; scientific research into preparations for manipulating and adapting human and animal cells; design and development of new products for others; scientific laboratory services; software as a service (SaaS) services featuring software for use in genomic data analysis; platform as a service (Paas) services that feature a computer bioinformatics platform for use in manufacturing therapeutics; providing a bioinformatics platform for identifying transcription factors to turn one cell type into another cell type; advisory and consultancy relating to all the aforesaid services

Classe 44

Medical services; veterinary services; medical services for the treatment of conditions of the human or animal body; medical services in the nature of manipulation of human and animal cells for therapeutic purposes; providing advice and consultancy in the field of medical and veterinary therapies

Publicações

Histórico de despachos e eventos da marca no USPTO.

32 publicações encontradas

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

27/07/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

04/01/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

13/12/2021

FIMP

FINAL DISPOSITION PROCESSED

13/12/2021

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

27/10/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

27/07/2021

GPNX

NOTIFICATION PROCESSED BY IB

11/05/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

11/05/2021

PUBO

PUBLISHED FOR OPPOSITION

11/05/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

21/04/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

21/04/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

21/04/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

02/04/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

02/04/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

02/04/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

02/04/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

02/04/2021

GNFN

NOTIFICATION OF FINAL REFUSAL EMAILED

25/03/2021

GNFR

FINAL REFUSAL E-MAILED

25/03/2021

CNFR

FINAL REFUSAL WRITTEN

25/03/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

04/03/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

04/03/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

04/03/2021

RFNT

REFUSAL PROCESSED BY IB

04/10/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

11/09/2020

RFRR

REFUSAL PROCESSED BY MPU

11/09/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

12/08/2020

CNRT

NON-FINAL ACTION WRITTEN

11/08/2020

DOCK

ASSIGNED TO EXAMINER

10/08/2020

MAFR

APPLICATION FILING RECEIPT MAILED

25/07/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

21/07/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

16/07/2020

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace MOGRIFY ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.